This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Thermo Fisher Scientific is a scientific instrument maker and a world leader in serving science. In Nov 2006, Thermo Fisher Scientific, Inc. was formed through the merger of Thermo Electron Corporation with Fisher Scientific International Inc. On Feb 3, 2014, Thermo Fisher acquired Life Technologies Corporation. Following the acquisition, the new reporting segments are: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.
Tandem Diabetes' (TNDM) Insulin Pump Approved by Health Canada
by Zacks Equity Research
Tandem Diabetes' (TNDM) t:slim X2 Insulin Pump with Control-IQ Advanced Hybrid Closed-Loop Technology cleared for use in Canada post the receipt of Health Canada approval.
Here's Why You Should Invest in Cooper Companies (COO) Stock
by Zacks Equity Research
Cooper Companies (COO) continues to benefit from solid CVI and CSI product portfolios.
Ecolab (ECL) Gets EPA Nod for Biofilm Disinfectant Virasept
by Zacks Equity Research
Ecolab's (ECL) Virasept has been developed to combat bacterial growth in hospitals.
NEOGEN (NEOG), Transnetyx Partner to Advance Mouse Genotyping
by Zacks Equity Research
NEOGEN (NEOG) aims to better serve the biomedical research community with a comprehensive and affordable solution for the genetic background testing of their mouse models via the partnership.
COVID-19 Vaccine Rollout Challenges Put These Stocks in Focus
by Rimmi Singhi
With COVID-19 vaccine on the horizon, cold-chain storage stocks including TT, CARR and TMO; vial makers like GLW and WST; and logistic operators including UPS and FDX are set to hog the limelight.
Here's Why You Should Add DaVita (DVA) to Your Portfolio Now
by Zacks Equity Research
Investor confidence is high on DaVita (DVA) stock, thanks to solid prospects.
5 Top Dividend Growth Stocks to Buy on the Cheap
by Sweta Killa
Honing in on stocks with a history of dividend growth leads to a healthy portfolio, with greater scope of capital appreciation as opposed to simple dividend-paying stocks or those with high yields.
Here's Why You Should Avoid Betting on Integer Holdings (ITGR)
by Zacks Equity Research
Stiff competition in the MedTech space and weak segmental and operational third-quarter 2020 performance weighs on Integer Holdings (ITGR).
QIAGEN (QGEN), BioNTech to Develop Test to Identify SCCHN
by Zacks Equity Research
QIAGEN (QGEN) aims to leverage its global reach and position in CDx and HPV testing by collaborating with BioNTech.
Zacks Industry Outlook Highlights: ResMed, Thermo Fisher Scientific, IDEXX Laboratories and STERIS
by Zacks Equity Research
Zacks Industry Outlook Highlights: ResMed, Thermo Fisher Scientific, IDEXX Laboratories and STERIS
Thermo Fisher's (TMO) Shares March Higher, Can It Continue?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Thermo Fisher Scientific (TMO).
Allscripts' (MDRX) Veradigm Collaborates With HealthVerity
by Zacks Equity Research
Allscripts (MDRX) and HealthVerity will be committed toward catering to specific industry needs by helping clients design linked data solutions that are fit-for-purpose.
Hologic's (HOLX) Cervical Cancer Screening System Gets CE Mark
by Zacks Equity Research
Hologic (HOLX) becomes the provider of the first CE-Marked comprehensive cervical cancer screening portfolio with the new Genius Digital Diagnostics System.
Here's Why You Should Hold NextGen (NXGN) in Your Portfolio Now
by Zacks Equity Research
Investor optimism is high on NextGen (NXGN) stock, thanks to solid prospects.
3 Best Buys from the Prospering Medical Instruments Industry
by Urmimala Biswas
Despite the challenges posed by the COVID-19 pandemic, higher demand for lab-testing products, digital influence, and AI and robotics is likely to lend support to the Zacks Medical - Instruments industry. TMO, IDXX and STE are well positioned to gain.
Here's Why You Should Hold on to QIAGEN (QGEN) Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about QIAGEN (QGEN) on robust segmental and geographical growth.
Medtronic's (MDT) Medicrea Buyout to Aid AI Spinal Surgery Line
by Zacks Equity Research
Medtronic (MDT) expects Medicrea's capabilities and solutions to complement its fully-integrated procedural solution for surgical planning and delivery.
QIAGEN (QGEN) Launches PCR Test, Expands Testing Portfolio
by Zacks Equity Research
QIAGEN (QGEN) aims to expand its NeuMoDx testing menu with the latest test launch and label extension.
Teleflex (TFX) Hurt by COVID-19-Led Disruption, UroLift Grows
by Zacks Equity Research
Teleflex (TFX) expects further adverse financial impact of the coronavirus pandemic.
AngioDynamics (ANGO) Shows Solid Results from RAPID Database
by Zacks Equity Research
The RAPID study proved that AngioDynamics' (ANGO) AngioVac System was versatile, safe and effective for the removal of vascular thrombi and cardiac masses.
Here's Why You Should Add Hologic (HOLX) to Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about Hologic (HOLX) on robust growth of the Diagnostics segment and regulatory approvals.
Hologic (HOLX) Updates Its Unifi Platform, Enhances Portfolio
by Zacks Equity Research
Hologic (HOLX) introduces upgrades to its Unifi Analytics platform to help mammography centers improve their workflow.
Ecolab Introduces Exelerate TUFSOIL for Food Manufacturers
by Zacks Equity Research
Ecolab's (ECL) Exelerate TUFSOIL has been developed to increase production time and enhance cleaning outcomes to curb food safety risks and improve worker safety.
Abbott (ABT) Launches Radiofrequency Ablation Device in U.S.
by Zacks Equity Research
Abbott (ABT) aims to expand its Neuromodulation portfolio with the latest launch of its radiofrequency ablation device.
Becton Dickinson (BDX) Buys Medical Business Assets of CUBEX
by Zacks Equity Research
This should further boost BD's (BDX) Medical segment.